olaparib

Aug 4, 2022

Merck, AstraZeneca Net European Approval for Adjuvant Lynparza in BRCA-Mutated Early Breast Cancer

Jul 29, 2022

AstraZeneca Q2 Oncology Sales Grow 14 Percent as Firm Awaits Key Precision Drug Regulatory Decisions
Premium

Jul 28, 2022

Merck's Keytruda Q2 Sales Grow 26 Percent; Firm Considers Future Impact of Medicare Price Setting
Premium

Jul 13, 2022

Oncologists Seeing Lack of PARP Inhibitor Response in MSI-High, BRCA-Mutant Prostate Cancer Patients

Jul 7, 2022

Doctors, Payors, Lab Directors, Patients Have Distinct Views on What's Holding Up Precision Oncology

Jun 27, 2022

EMA's CHMP Backs Approval for Enhertu, Lynparza for Two Breast Cancer Indications

Jun 22, 2022

Agendia Building Validation Data on ImPrint for Guiding Neoadjuvant Immunotherapy in Breast Cancer
Premium

Apr 28, 2022

Merck Q1 Revenues Increase 50 Percent Driven by Keytruda

Apr 11, 2022

UPenn Researchers Enrolling BRCA1/2 Carriers Into Inovio hTERT Cancer Vaccine study

Mar 17, 2022

Lynparza Survival Benefit, FDA Approval in Early-Stage Breast Cancer Could Broaden Genetic Testing
Premium

Mar 11, 2022

FDA Approves Lynparza as Adjuvant Therapy With Myriad Genetics CDx for BRCA-Mutated Breast Cancer

Feb 18, 2022

PARP Inhibitors Show Frontline Prostate Cancer Benefit; Conflicting Biomarker Data Raise Questions
Premium

Feb 10, 2022

AstraZeneca Q4 Oncology Revenues Grow 20 percent

Feb 3, 2022

Merck Q4 Revenues Grow 24 Percent With Keytruda Driving Sales

Nov 30, 2021

AstraZeneca, Merck File Adjuvant Lynparza sNDA for Early-Stage Breast Cancer

Nov 12, 2021

AstraZeneca's Q3 Oncology Revenues Grow 18 Percent

Oct 28, 2021

Merck Q3 Revenues Grow 20 Percent With Keytruda as Top Seller

Sep 7, 2021

Illumina, Merck Partner to Advance Homologous Recombination Deficiency CDx, Research Assay

Aug 4, 2021

Clovis Oncology's Q2 Rubraca Sales Dip 8 Percent

Jul 29, 2021

Merck Q2 Revenues Grow 22 Percent